These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19095950)

  • 61. Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer.
    Wu RC; Young IC; Chen YF; Chuang ST; Toubaji A; Wu MY
    Nat Commun; 2019 Sep; 10(1):4332. PubMed ID: 31551414
    [TBL] [Abstract][Full Text] [Related]  

  • 62. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
    Jiang BH; Liu LZ
    Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
    [TBL] [Abstract][Full Text] [Related]  

  • 63. MicroRNA-146b promotes PI3K/AKT pathway hyperactivation and thyroid cancer progression by targeting PTEN.
    Ramírez-Moya J; Wert-Lamas L; Santisteban P
    Oncogene; 2018 Jun; 37(25):3369-3383. PubMed ID: 29353884
    [TBL] [Abstract][Full Text] [Related]  

  • 64. c-Myc phosphorylation by PKCζ represses prostate tumorigenesis.
    Kim JY; Valencia T; Abu-Baker S; Linares J; Lee SJ; Yajima T; Chen J; Eroshkin A; Castilla EA; Brill LM; Medvedovic M; Leitges M; Moscat J; Diaz-Meco MT
    Proc Natl Acad Sci U S A; 2013 Apr; 110(16):6418-23. PubMed ID: 23550155
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.
    He L; Ingram A; Rybak AP; Tang D
    J Clin Invest; 2010 Jun; 120(6):2094-108. PubMed ID: 20458142
    [TBL] [Abstract][Full Text] [Related]  

  • 66. RapidCaP, a novel GEM model for metastatic prostate cancer analysis and therapy, reveals myc as a driver of Pten-mutant metastasis.
    Cho H; Herzka T; Zheng W; Qi J; Wilkinson JE; Bradner JE; Robinson BD; Castillo-Martin M; Cordon-Cardo C; Trotman LC
    Cancer Discov; 2014 Mar; 4(3):318-33. PubMed ID: 24444712
    [TBL] [Abstract][Full Text] [Related]  

  • 67. IRS2 is a candidate driver oncogene on 13q34 in colorectal cancer.
    Day E; Poulogiannis G; McCaughan F; Mulholland S; Arends MJ; Ibrahim AE; Dear PH
    Int J Exp Pathol; 2013 Jun; 94(3):203-11. PubMed ID: 23594372
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Interruption of KLF5 acetylation promotes PTEN-deficient prostate cancer progression by reprogramming cancer-associated fibroblasts.
    Zhang B; Liu M; Mai F; Li X; Wang W; Huang Q; Du X; Ding W; Li Y; Barwick BG; Ni JJ; Osunkoya AO; Chen Y; Zhou W; Xia S; Dong JT
    J Clin Invest; 2024 May; 134(14):. PubMed ID: 38781024
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Systemic elevation of PTEN induces a tumor-suppressive metabolic state.
    Garcia-Cao I; Song MS; Hobbs RM; Laurent G; Giorgi C; de Boer VC; Anastasiou D; Ito K; Sasaki AT; Rameh L; Carracedo A; Vander Heiden MG; Cantley LC; Pinton P; Haigis MC; Pandolfi PP
    Cell; 2012 Mar; 149(1):49-62. PubMed ID: 22401813
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ERBB2 Targeting Reveals a Significant Suppression of Tumorigenesis in Murine Endometrial Cancer with Pten Mutation.
    Dunston K; Hunter MI; Johannesen E; Jung JS; Kim TH; Yoo JY; Jeong JW
    Reprod Sci; 2024 Aug; 31(8):2458-2467. PubMed ID: 38637476
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Synthetic Essentiality of Metabolic Regulator PDHK1 in PTEN-Deficient Cells and Cancers.
    Chatterjee N; Pazarentzos E; Mayekar MK; Gui P; Allegakoen DV; Hrustanovic G; Olivas V; Lin L; Verschueren E; Johnson JR; Hofree M; Yan JJ; Newton BW; Dollen JV; Earnshaw CH; Flanagan J; Chan E; Asthana S; Ideker T; Wu W; Suzuki J; Barad BA; Kirichok Y; Fraser JS; Weiss WA; Krogan NJ; Tulpule A; Sabnis AJ; Bivona TG
    Cell Rep; 2019 Aug; 28(9):2317-2330.e8. PubMed ID: 31461649
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Behavioral stress accelerates prostate cancer development in mice.
    Hassan S; Karpova Y; Baiz D; Yancey D; Pullikuth A; Flores A; Register T; Cline JM; D'Agostino R; Danial N; Datta SR; Kulik G
    J Clin Invest; 2013 Feb; 123(2):874-86. PubMed ID: 23348742
    [TBL] [Abstract][Full Text] [Related]  

  • 73. PTEN mRNA detection by chromogenic, RNA in situ technologies: a reliable alternative to PTEN immunohistochemistry.
    Bingham V; Ong CW; James J; Maxwell P; Waugh D; Salto-Tellez M; McQuaid S
    Hum Pathol; 2016 Jan; 47(1):95-103. PubMed ID: 26518664
    [TBL] [Abstract][Full Text] [Related]  

  • 74. HER2 overcomes PTEN (loss)-induced senescence to cause aggressive prostate cancer.
    Ahmad I; Patel R; Singh LB; Nixon C; Seywright M; Barnetson RJ; Brunton VG; Muller WJ; Edwards J; Sansom OJ; Leung HY
    Proc Natl Acad Sci U S A; 2011 Sep; 108(39):16392-7. PubMed ID: 21930937
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Deletion of Irs2 causes reduced kidney size in mice: role for inhibition of GSK3beta?
    Carew RM; Sadagurski M; Goldschmeding R; Martin F; White MF; Brazil DP
    BMC Dev Biol; 2010 Jul; 10():73. PubMed ID: 20604929
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Luminal cells are favored as the cell of origin for prostate cancer.
    Wang ZA; Toivanen R; Bergren SK; Chambon P; Shen MM
    Cell Rep; 2014 Sep; 8(5):1339-46. PubMed ID: 25176651
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Portrait of PTEN: messages from mutant mice.
    Suzuki A; Nakano T; Mak TW; Sasaki T
    Cancer Sci; 2008 Feb; 99(2):209-13. PubMed ID: 18201277
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Modelling synergistic interactions between HER2, Sprouty2 and PTEN in driving prostate carcinogenesis.
    Ahmad I; Gao M; Patel R; Leung HY
    Asian J Androl; 2013 May; 15(3):323-7. PubMed ID: 23584380
    [No Abstract]   [Full Text] [Related]  

  • 79. Expression of IRS2 in the female reproductive system during the estrous cycle in mice.
    Wang Z; Yi B; Gan L; Li X; Liu X; Lv Q; Yang L
    Biotech Histochem; 2023 Apr; 98(3):187-192. PubMed ID: 36472073
    [TBL] [Abstract][Full Text] [Related]  

  • 80. PTEN in cancer, metabolism, and aging.
    Ortega-Molina A; Serrano M
    Trends Endocrinol Metab; 2013 Apr; 24(4):184-9. PubMed ID: 23245767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.